News Image

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Provided By GlobeNewswire

Last update: Aug 12, 2024

BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination cohorts; initial proof-of-concept data now expected in the second half of 2025

Read more at globenewswire.com

BOUNDLESS BIO INC

NASDAQ:BOLD (2/24/2025, 11:38:55 AM)

1.88

-0.08 (-4.08%)



Find more stocks in the Stock Screener

Follow ChartMill for more